glp-1 signaling New Insights into Beta-Cell Receptor and cAMP Frontiers | GLP-1 Suppresses Feeding
Description
F.DinanT
This study is the first to examine the potential cardiovascular benefits of these drugs in a high-risk population of patients with both obesity and an autoimmune diseaseboth of which are associated with a higher risk of cardiovascular and blood clot events
Although the R131 1.26b N mutation did not significantly affect GLP-1 action (Koole et al., 2011), Beinborn and colleagues showed that the T149 1.44b M mutation (which has been associated with T2DM) led to a 60-fold reduction in GLP-1 affinity and a 30-fold reduction in potency (Tokuyama et al., 2004
Key Findings Diabetes-related findings: Over a 30-month period, users of GLP-1s for diabetes experienced a slower increase in medical cost growth compared to non-users
Throughout this article, recommendations are tagged as [ADA], [NICE], or [Both] so you can quickly see which guideline applies to your practice setting
Liaqat H, Parveen A, Kim SY
